Murad Khan, Suleman Shah, Wahid Shah, Ikram Khan, Hamid Ali, Ijaz Ali, Riaz Ullah, Xiufang Wang, Arshad Mehmood, Yanli Wang
{"title":"Gut microbiome as a treatment in colorectal cancer.","authors":"Murad Khan, Suleman Shah, Wahid Shah, Ikram Khan, Hamid Ali, Ijaz Ali, Riaz Ullah, Xiufang Wang, Arshad Mehmood, Yanli Wang","doi":"10.1080/08830185.2024.2312294","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The gut microbiome plays a role in the development and progression of colorectal cancer (CRC).</p><p><strong>Aim and objective: </strong>This review focuses on whether the gut microbiome is involved in the development and regulation of the host immune system.</p><p><strong>Methods: </strong>The gut microbiome can influence the production and activity of immune cells and molecules that help to maintain the integrity of the intestinal barrier and prevent inflammation. Gut microbiota modulates the anti-cancer immune response. The gut microbiota can influence the function of immune cells, like T cells, that recognize and eliminate cancer cells. Gut microbiota can affect various aspects of cancer progression and the efficacy of various anti-cancer treatments.</p><p><strong>Results: </strong>Gut microbiota provide promise as a potential biomarker to identify the effect of immunotherapy and as a target for modulation to improve the efficacy of immunotherapy in CRC treatment.</p><p><strong>Conclusion: </strong>The potential synergistic effect between the gut microbiome and anti-cancer treatment modalities provides an interest in developing strategies to modulate the gut microbiome to improve the efficacy of anti-cancer treatment.</p>","PeriodicalId":14333,"journal":{"name":"International Reviews of Immunology","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Reviews of Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08830185.2024.2312294","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/12 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The gut microbiome plays a role in the development and progression of colorectal cancer (CRC).
Aim and objective: This review focuses on whether the gut microbiome is involved in the development and regulation of the host immune system.
Methods: The gut microbiome can influence the production and activity of immune cells and molecules that help to maintain the integrity of the intestinal barrier and prevent inflammation. Gut microbiota modulates the anti-cancer immune response. The gut microbiota can influence the function of immune cells, like T cells, that recognize and eliminate cancer cells. Gut microbiota can affect various aspects of cancer progression and the efficacy of various anti-cancer treatments.
Results: Gut microbiota provide promise as a potential biomarker to identify the effect of immunotherapy and as a target for modulation to improve the efficacy of immunotherapy in CRC treatment.
Conclusion: The potential synergistic effect between the gut microbiome and anti-cancer treatment modalities provides an interest in developing strategies to modulate the gut microbiome to improve the efficacy of anti-cancer treatment.
背景:肠道微生物组在结肠直肠癌(CRC)的发生和发展过程中发挥着作用:本综述重点探讨肠道微生物组是否参与宿主免疫系统的发育和调节:肠道微生物群可影响免疫细胞和分子的产生与活性,从而帮助维持肠道屏障的完整性并预防炎症。肠道微生物群调节抗癌免疫反应。肠道微生物群能影响免疫细胞(如 T 细胞)的功能,而 T 细胞能识别并消灭癌细胞。肠道微生物群可影响癌症进展的各个方面以及各种抗癌疗法的疗效:结果:肠道微生物群有望成为识别免疫疗法效果的潜在生物标志物,也有望成为提高免疫疗法在 CRC 治疗中疗效的调节靶点:结论:肠道微生物群与抗癌治疗方法之间的潜在协同作用,为制定调节肠道微生物群的策略以提高抗癌治疗效果提供了兴趣所在。
期刊介绍:
This review journal provides the most current information on basic and translational research in immunology and related fields. In addition to invited reviews, the journal accepts for publication articles and editorials on relevant topics proposed by contributors. Each issue of International Reviews of Immunology contains both solicited and unsolicited review articles, editorials, and ''In-this-Issue'' highlights. The journal also hosts reviews that position the authors'' original work relative to advances in a given field, bridging the gap between annual reviews and the original research articles.
This review series is relevant to all immunologists, molecular biologists, microbiologists, translational scientists, industry researchers, and physicians who work in basic and clinical immunology, inflammatory and allergic diseases, vaccines, and additional topics relevant to medical research and drug development that connect immunology to disciplines such as oncology, cardiovascular disease, and metabolic disorders.
Covered in International Reviews of Immunology: Basic and developmental immunology (innate and adaptive immunity; inflammation; and tumor and microbial immunology); Clinical research (mechanisms of disease in man pertaining to infectious diseases, autoimmunity, allergy, oncology / immunology); and Translational research (relevant to biomarkers, diagnostics, vaccines, and drug development).